Ciclosporin ophthalmic - Laboratoires Thea
Alternative Names: T-1580; T1580 ophthalmicLatest Information Update: 15 Feb 2022
At a glance
- Originator Laboratoires Thea
- Class Anti-inflammatories; Antineoplastics; Antipsoriatics; Antirheumatics; Ciclosporins; Eye disorder therapies; Heart failure therapies; Neuroprotectants
- Mechanism of Action Calcineurin inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors; P-glycoprotein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Dry eyes
Most Recent Events
- 15 Feb 2022 Phase III development in Dry eyes is ongoing in Belgium and Italy (EudraCT2015-005405-36)
- 15 Feb 2022 No development reported - Phase-III for Dry eyes (In the elderly, In adults) in United Kingdom, Spain, Poland, Czech Republic, Croatia, Bulgaria, Greece, Lithuania, Austria, Latvia, Hungary (Ophthalmic)
- 17 May 2016 Phase-III clinical trials in Dry eyes (In adults, In the elderly) in Greece, Lithuania, Austria, Latvia, Hungary (Ophthalmic) (EudraCT2015-005405-36)